Insurer denials for hepatitis C treatment remain high
Skip to main content
Sister Publication Links
  • Modern Healthcare Metrics
MDHC_Logotype_white
Subscribe
  • Subscribe
  • Register
  • Login
  • News
    • This Week's News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • People
    • Regional News
    • Digital Edition
    • House GOP leaders introduce drug-pricing bill to counter Pelosi plan
      IHI releases principles to improving patient safety measures
      Plan members unlikely to benefit from Supreme Court risk corridor battle
      Connecticut tentatively resolves hospital spat over taxes
    • Not-for-profit hospitals stabilized by Medicare pay raise, DSH cut delays
      November was healthcare's second strongest hiring month of 2019
      Primary-care provider ChenMed to enter five new markets
      Lacking specialist access drives health disparities
    • Plan members unlikely to benefit from Supreme Court risk corridor battle
      Joan Budden
      Q&A: Priority Health CEO eager to share best practices with Total Health Care
      Silver-loading, CSR elimination lowered premiums for some rural enrollees
      Centene to sell Illinois plan to CVS Health
    • Capitol Building with pills
      Week Ahead: House to vote on drug bill; SCOTUS hears risk-corridor case
      MedPAC thinks hospice payments are too high
      MedPAC says ambulatory surgical centers don't need a pay raise
      States focus on healthcare costs to address coverage problems
    • Analysts to CommonSpirit Health: Show us the savings
      Smallest hospitals saw biggest earnings gains last month
      Sutter Health postpones financial filing
      doctor helping patient stock image Sandoz
      Sponsored Content Provided By Sandoz
      As hospital executives look to reduce costs, biosimilars offer a compelling option
    • astronaut
      Astronauts developed bloodstream issues in space
      Sponsored Content Provided By ABM Healthcare
      Protecting and Maintaining Medical Devices
      human hand robotic hand stock image
      Sponsored Content Provided By Deloitte
      The Health System of the Future: How Digital Health Technology is Transforming Care
      EHR
      EHR vendors most in-use throughout Medicare incentive program
    • IHI releases principles to improving patient safety measures
      MRIs of dense breasts find more cancer but also false alarms
      Flu season takes off quickly in Deep South states
      Uber driver says South Carolina hospital dumped patient on him
    • Trinity Health appoints new COO: Ben Carter
      Jim Allison playing the harmonica
      Documentary tells tale of Nobel winning researcher
      Seema Verma
      Seema Verma's bold initiatives land her in No. 1 Most Influential spot
      New CEO takes the helm at Lurie Children's Hospital of Chicago
    • Midwest
    • Northeast
    • South
    • West
  • Special Features
    • Best Practices
    • InDepth Special Reports
    • Innovations
    • Chest x-ray from a patient with a vaping-related lung injury
      Vaping-related cases lead to care guidelines from Intermountain
      Arkansas Children’s was a founding partner in Solutions for Patient Safety.
      Children's hospitals collaborate rather than compete on patient safety
      Peer recovery specialists at St. Barnabas Medical Center work with nurse Brenna Zarra.
      Peer recovery helping patients with addiction seek treatment
      UNC Health Care trains staff to treat dementia patients
    • Linda Kenney
      Patient advocate recalls two medical errors that nearly killed her
      Leah Binder, CEO of the Leapfrog Group, with her grandmother, Estelle Greifer.
      With no national reporting system, volume of medical errors is still unknown
      Man in hospital bed
      Minnesota looks to evolve its patient-safety reporting system
      Dr. Don Berwick
      Despite progress, we’re still waiting for a truly safer healthcare system
    • Randy Oostra, CEO of ProMedica
      HCR ManorCare deal laid foundation for ProMedica’s growth
      Advanced ICU Care
      Telemedicine helps rural hospitals meet intensivist shortage
      Paging Dr. Robot: Artificial intelligence moves into care
      A child being screened for vision problems using a smartphone.
      App screens kids for eye problems before they can talk
  • Transformation
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • ProMedica doubles down on social needs data analysis
      Amazon taps first pharmacy for Alexa Rx management
      Trump administration unveils new price transparency rules
      A child being screened for vision problems using a smartphone.
      App screens kids for eye problems before they can talk
    • VA dives into artificial intelligence R&D
      Home health to pare down therapy services, up telehealth offerings
      Amazon launches medical transcription service
      Hospitals' uncompensated care continues to rise
    • Chest x-ray from a patient with a vaping-related lung injury
      Vaping-related cases lead to care guidelines from Intermountain
      Advanced ICU Care
      Telemedicine helps rural hospitals meet intensivist shortage
      Peer recovery specialists at St. Barnabas Medical Center work with nurse Brenna Zarra.
      Peer recovery helping patients with addiction seek treatment
      UNC Health Care trains staff to treat dementia patients
    • Value-based pay still struggles to improve costs, quality
      Hospitals sue HHS over negotiated price disclosure rule
      Bundled payments get a boost in two states with employee programs
      CMS wants primary-care docs to take on financial risk
  • Data/Lists
    • Rankings/Lists
    • Data Points
    • Modern Healthcare Metrics
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
    • Randy Oostra, CEO of ProMedica
      HCR ManorCare deal laid foundation for ProMedica’s growth
      Steve Strongwater
      How Atrius Health stayed independent by not shying away from risk
      Why moving the VA to a new EHR was a pivotal decision
      Why AdventHealth's rebrand was more than a name change
    • Terry Shaw
      A diverse and inclusive culture should empower others
      Paving the path to diversity and inclusion
      The next step in healthcare evolution
      Breaking Bias: A road map to boost women and minorities into healthcare leadership
    • Dr. Richard Snyder
      Outdated privacy laws hinder coordinated care, especially in the fight against addiction
      David Dill and Keith Myers
      Healthcare partnerships are a proven path to better care, healthier communities
      Health systems need to devote more resources to caring for the caregivers
      Fawn Lopez and Bernard Tyson
      In remembrance and gratitude for a life well-lived
    • Letters: Let’s keep humanity in discussions about patient safety
      Hospital with money
      Letters: Let providers set their prices,
 and then publish them all
      Letters: Ambulatory surgery centers aren't getting a break on regulation
      Letters: Rising Medicaid spending isn't a windfall for providers
    • Sponsored Content Provided By Optum
      How blockchain could ease frustration with the payment process
      Sponsored Content Provided By Optum
      Three steps to better data-sharing for payer and provider CIOs
      Sponsored Content Provided By Optum
      Reduce total cost of care: 6 reasons why providers and payers should tackle the challenge together
      Sponsored Content Provided By Optum
      Why CIOs went from back-office operators to mission-critical innovators
  • Awards
    • Nominate
    • Award Programs
    • Previous Award Programs
    • Other Award Programs
    • Nominations Open - Top 25 Minority Leaders
      Nominations Open - Health Care Hall of Fame
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Top 25 Minority Leaders
    • Top 25 Women Leaders
    • Excellence in Nursing Awards
    • Design Awards
    • Top 25 COOs in Healthcare
    • 100 Top Hospitals
    • ACHE Awards
  • Events
    • Conferences
    • Galas
    • Webinars
    • Kronos webinar logo lockup
      Sponsored Content Provided By Kronos
      Webinar: The Future of Work in Healthcare
    • Leadership Symposium
    • Healthcare Transformation Summit
    • Critical Connections: Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Workplace of the Future Conference
    • Strategic Marketing Conference
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Minority Leaders Gala (2020)
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
June 07, 2018 01:00 AM

Insurer denials for hepatitis C treatment remain high

Shelby Livingston
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print

    Despite the availability of hepatitis C drugs capable of curing most patients, public and private health insurers denied treatment for more than a third of patients whose doctors prescribed the drugs between 2016 and April 2017, according to a study.

    Insurance denials were high across all types of insurance plans despite efforts by policymakers and patient advocates to remove reimbursement restrictions, but treatment for commercially insured patients was denied more often than for patients enrolled in Medicaid or Medicare, according to the study published Thursday in the Open Forum Infectious Diseases journal.

    "I think much of it is a consequence of the cost of the drugs, which are anywhere from $35,000 to $100,000 for the treatment course," said Dr. Vincent Lo Re, the study's senior author and an associate professor of infectious disease and epidemiology at the University of Pennsylvania's Perelman School of Medicine.

    The hepatitis C drugs, known as direct-acting antiviral drugs, first became available in 2014 and cure about 95% of people with chronic hepatitis C, a viral liver disease that can cause liver failure or death. It affects about 3.5 million people and kills 19,000 a year, according to the Centers for Disease Control and Prevention.

    Examples of the drugs include Harvoni, Sovaldi, Epclusa and Mavyret. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommend these direct-acting antiviral therapies for the treatment of hepatitis C. But the drugs come with high price tags. Harvoni, for example, costs $94,500 for a 12-week course.

    Researchers expected denials would have decreased as public health officials gave the disease a vast amount of attention and many new treatments have come to market in recent years.

    Researchers analyzed the prevalence of insurance denials among 9,025 patients in 45 states who were prescribed the hepatitis C treatment between January 2016 and April 2017. The data came from Diplomat Pharmacy, one of the largest specialty pharmacies, which was chosen for the study because of its national footprint.

    Of the patients prescribed treatment, 3,200, or 35.5%, received a denial from their insurer. Insurers' requests for alternative oral drug treatments because of formulary restrictions were not counted as denials.

    Insurers' denials increased over the length of the study period, from a rate of 27.7% in the first quarter to 43.8% in the final quarter of the study.

    Commercially insured patients, meaning those who were covered by employer-sponsored insurance or who bought coverage on the individual market, received a denial for treatment more than half the time at 52.4%. Insurers denied treatment for 34.5% of Medicaid beneficiaries and 14.7% for Medicare enrollees.

    Insurance industry lobbying group America's Health Insurance Plans said the study "paints a misleading and inconclusive picture of coverage of antiviral therapy for patients suffering from hepatitis C" because it doesn't reflect whether prescriptions were later approved after an appeal, and relies on the data of one specialty pharmacy with claims concentrated in a handful of states. AHIP also said that because the study didn't look at the reasons for insurer denials, researchers do not know which claims for hepatitis C treatment were clinically appropriate.

    Researchers noted that the study was limited by their inability to analyze specific reasons that insurers denied coverage for treatment. That's because while insurers may tell patients why they denied coverage, they don't tell the specialty pharmacies, so that data was unavailable.

    Denials also have increased when compared with the rate of denials found by two prior studies published in 2016, the study found. Many insurers restrict reimbursement to only the sickest patients, those who are sober, or those who have seen a specialist. It's likely that patients who receive denials didn't have severe enough liver damage, or were active alcohol or drug users, the study notes.

    Denials may have also increased over the years because physicians are seeing patients with less severe liver damage more often. When the new hepatitis C drugs first came out, physicians treated patients with very advanced liver fibrosis and cirrhosis who had been waiting years for treatment, Lo Re said. But now that those patients have been treated, doctors are often seeing patients with less damage, he said.

    Insurers place reimbursement restrictions on the drugs to save money, but Lo Re said the hepatitis C drug treatments help to eliminate downstream costs.

    "Studies show even at minimal stages of liver fibrosis you are saving enormous healthcare dollars by avoiding all the downstream costs of things like liver transplants, hospitalizations to manage end-stage liver disease, and liver cancer," he said.

    The CMS in late 2015 warned states that restricting access to the drugs based on saving costs could violate federal law. After that, class action lawsuits and other litigation against state Medicaid programs sprang up, prompting changes to Medicaid reimbursement of the drugs. But less is known about commercial and Medicare reimbursement.

    The rate of denials among commercially insured patients is likely the highest because most attention for hepatitis C drug reimbursement has been directed toward public programs, Lo Re said.

    "It warrants greater attention from public health sector, policymakers and advocates to continue to draw attention to access to these drugs, because if we are going to achieve the elimination of hepatitis C as a public health problem … we need to treat a sufficient enough people with chronic hepatitis C to be able to eliminate it," Lo Re said.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Sponsored Content
    Get Free Newsletters

    Sign up for free enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today

    The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. We help you make informed business decisions and lead your organizations to success.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS
    • Instagram

    Stay Connected

    Join the conversation with Modern Healthcare through our social media pages

    MDHC_Logotype_white
    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    Modern Healthcare
    Copyright © 1996-2019. Crain Communications, Inc. All Rights Reserved.
    • News
      • This Week's News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition
    • Special Features
      • Best Practices
      • InDepth Special Reports
      • Innovations
    • Transformation
      • Patients
      • Operations
      • Care Delivery
      • Payment
    • Data/Lists
      • Rankings/Lists
      • Data Points
      • Modern Healthcare Metrics
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate
      • Award Programs
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Top 25 Minority Leaders
        • Top 25 Women Leaders
      • Previous Award Programs
        • Excellence in Nursing Awards
        • Design Awards
        • Top 25 COOs in Healthcare
      • Other Award Programs
        • 100 Top Hospitals
        • ACHE Awards
    • Events
      • Conferences
        • Leadership Symposium
        • Healthcare Transformation Summit
        • Critical Connections: Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
        • Workplace of the Future Conference
        • Strategic Marketing Conference
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Minority Leaders Gala (2020)
      • Webinars
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing